deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT03119662

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in Adults With Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR)

Sponsor: GE Healthcare

Conditions Chronic Kidney Diseases
Interventions Placebos Visipaque
Updated 18 times since 2017 Last updated: Nov 28, 2019 Started: Feb 8, 2018 Primary completion: Sep 13, 2018 Completion: Oct 19, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The trial was discontinued due to a lower than anticipated recruitment rate. The decision has not been made due to any safety reasons.

Other terminated trials from GE Healthcare

See all terminations from GE Healthcare

A PHASE4 clinical study on Chronic Kidney Diseases, this trial is terminated or withdrawn. The trial is conducted by GE Healthcare and has accumulated 18 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2017 – ~Dec 2017 · 7 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2020 · 14 months · monthly snapshot~Jan 2020 – ~Nov 2020 · 10 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE4

▶ Show 13 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE4

  2. Jan 2020 — Nov 2020 [monthly]

    Terminated PHASE4

  3. Nov 2018 — Jan 2020 [monthly]

    Terminated PHASE4

    Status: Recruiting → Terminated

  4. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE4

  5. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE4

  6. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE4

  7. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE4

  8. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE4

  9. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  10. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE4

  11. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE4

  12. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  13. May 2017 — Dec 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GE Healthcare
  • Syneos Health
Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Birmingham, United States , Boston, United States , Burlington, United States , Bytom, Poland , Cadiz, Spain , Chapel Hill, United States , Dallas, United States , Doral, United States , Duluth, United States and 19 more locations